Imagine a high-tech camera that can see how blood flows in your tiniest vessels without needing a needle or a blood test. It's like using a specialized light pattern to spot early warning signs of heart failure before they become serious. The goal is to make this as simple as sitting on a smart toilet to check your health automatically.
Cardiovascular diseases cost the EU over 210B€ annually due to late detection. Current monitoring often requires invasive procedures or active patient participation, leading to missed early signs of heart and kidney failure.
A 3D speckle tissue monitoring instrument and digital biomarkers for microcirculation, including a smart-toilet application for unobtrusive health tracking.
If you are a device manufacturer dealing with the need for more accurate home diagnostics — this project developed 3D speckle tissue monitoring that helps capture digital biomarkers for heart failure. This targets a market expected to surpass 5 B$ by 2030.
If you are a wearable brand dealing with a saturated market of basic step-counters — this project developed a way to assess microcirculatory status. This allows you to enter the wearable technology market, which is expected to grow to 392 B$ by 2030.
If you are a home automation company dealing with the demand for elderly care — this project developed a smart-toilet application for unobtrusive monitoring. This helps reduce hospitalization for the old age population by detecting chronic conditions early.
The project estimates that the new instrument and digital biomarkers can reduce the healthcare burden by over 30% and indirect healthcare costs by over 20% through timely intervention.
Yes, the technology targets the RPM market (expected to surpass 5 B$ by 2030) and the wearable market (expected to grow to 392 B$ by 2030), with over 1 billion current wearable users globally.
Based on available project data, the project is in the development and validation phase via clinical trials; specific licensing terms are not provided.
The technology is designed for unobtrusive monitoring, specifically demonstrating a use-case within a smart-toilet application to avoid disrupting the patient's daily routine.
The project period runs from 2023-10-01 to 2027-09-30, during which instruments are developed and validated in clinical trials.
The consortium is heavily academic and research-oriented, consisting of 7 partners from 6 countries. It is led by Turku University (Finland) and includes 3 universities and 2 research organizations. Notably, there are 0 industry partners and 0 SMEs, indicating that the project is currently in a high-science phase and represents a significant opportunity for industrial partners to enter for commercialization.
Contact Turku University (Finland) regarding the STIMULUS project
Contact SciTransfer to facilitate a licensing discussion with the Turku University consortium.
